Dr. Eric Topol recently posted an interesting image on Twitter. According the US Bureau of Labor Statistics, Healthcare jobs exceeded Retail jobs: We believe this is unsustainable, as…
Deloitte recently published their annual report on returns generated by big pharma from their R&D investments. The PDF report is available here. The report is divided into two sections.…
As a pharmaceutical scientist, the concept of "synthetic biology" sounds somewhat oxymoronic. It's true that our industry has been manipulating genes and cells to produce peptides, proteins, and other…
What did we find interesting about 2017? What will happen in 2018? Our brief video summarizes our thoughts on the year that's coming to a close, and also discusses…
As of this writing, there are 100 days until we're wheels up and on our way to BIOEurope Spring in Amsterdam. Many believe it is too soon to think…
It's amazing how months of preparation for a conference are realized in 4-5 intense days. From Sunday afternoon until the wee hours of Thursday morning, BIO-Europe in Berlin was…
Simple question...is our industry risk averse? Some would say, "Yes, absolutely." Look at psychiatric drugs, as an example. When the SSRIs were launched in the early 1990s, it was a…
The recent news that Novartis is closing its Colorado-based generics manufacturing facility brought back a few memories. A company spokesperson blamed "above-average pricing pressure". The products were described as "oral...for…
Is out-licensing difficult? Yes, of course it is. But how difficult is it? Is this something which can be quantified? And, why would we want to quantify this anyway? These…
This post is in response to a prospective client, who asked us about the required depth and complexity required in a financial model(s) when out-licensing. It's an interesting question. So…